No Change in Standard of Care for HPV+ Oropharyngeal Cancer No Change in Standard of Care for HPV+ Oropharyngeal Cancer

Interim results of a large phase III trial showed that patients treated with a cetuximab regimen has worse survival than those treated with cisplatin plus radiation therapy.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

Condition:   Head and Neck Cancer Intervention:   Radiation: Radiation therapy Sponsor:   Dana-Farber Cancer Institute Not yet recruiting
Source: - Category: Research Source Type: clinical trials
AbstractRecent evidence suggests that reducing radiotherapy dose delivered to specific anatomical swallowing structures [Swallowing Organs at Risk (SWOARs)] may improve swallowing outcomes post-treatment for patients with head and neck cancer. However, for those patients with tumours of the oropharynx, which typically directly overlap the SWOARs, reducing dose to these structures may be unachievable without compromising on the treatment of the disease. To assess the feasibility of dose reduction in this cohort, standard IMRT plans (ST-IMRT) and plans with reduced dose to the SWOARs (SW-IMRT) were generated for 25 oropharyn...
Source: Dysphagia - Category: Speech-Language Pathology Source Type: research
Publication date: Available online 14 November 2018Source: Practical Radiation OncologyAuthor(s): C. Jillian Tsai, Sean M. McBride, Nadeem Riaz, Nancy Y. LeeAbstractData on the biology and radiosensitivity of human papillomavirus–related cancers have led many expert radiation oncologists to decrease the radiation dose to target areas in selected situations. At Memorial Sloan Kettering Cancer Center, we have altered our radiation guidelines to allow substantial dose reduction to elective treatment regions and to omit radiation completely in other regions that have historically been included in the elective treatment v...
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
We present our results in patients with recurrent head and neck cancers treated with HDR interstitial brachytherapy. Material and methods: Twenty-five patients with recurrent head and neck cancers were treated with HDR interstitial brachytherapy using Iridium 192 between 2009 and 2016. Of these, 75% received radical brachytherapy, and 25% received external beam radiation therapy (EBRT) followed by brachytherapy boost. Treatment sites included oral cavity (15/25) and oropharynx (10/25). Median dose of 4.5 Gy was administered twice per day, with median total brachytherapy dose of 40.5 Gy in radical and 27 Gy for EBRT cas...
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
We developed and implemented a data-driven decision support system for identifying those oropharyngeal cancer patients likely to have the greatest benefit from proton therapy. We found that younger patients with p16-positive tumors who smoked ≤10 pack-years were estimated to have the most quality-adjusted life years (QALYs) spared with proton therapy, as compared to photon IMRT. Importantly, the estimated benefit of proton therapy depends strongly on the organ-at-risk doses achievable with photon IMRT.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Physics Contribution Source Type: research
Developing a quantitative decision-support strategy estimating the impact of normal tissue complications from definitive radiation therapy (RT) for head and neck cancer (HNC). We developed this strategy to identify patients with oropharyngeal HNC who may benefit most from receiving proton RT.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Physics Contribution Source Type: research
In 2016, the World Health Organization provisionally classified Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) as a lymphoid neoplasm under the subcategory of mature B-cell neoplasms. Here we describe a 59-year-old Chinese woman with a long history of recurrent sinus and oropharyngeal infections and was diagnosed initially with EBVMCU and later, diffuse large B-cell lymphoma (DLBCL). She had sought medical attention after a particularly long bout of increased facial pressure and nasal obstruction. As a young adult she had undergone a tonsillectomy, adenoidectomy, and received innumerable treatments for bron...
Source: Blood - Category: Hematology Authors: Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies Source Type: research
Publication date: Available online 2 November 2018Source: Journal of Cancer PolicyAuthor(s): Sanjeeva Gunasekera, Sanjeewa Seneviratne, Thiw.a Wijeratne, Christopher M. BoothAbstractSri Lanka, a small island nation in South Asia, is in the process of transition from a low-middle to an upper middle income country. With these changes, the burden of non-communicable disease has increased significantly. Cancer incidence has nearly doubled in twenty-five years. The pattern of cancer is also changing with breast, lung and colorectal cancers showing marked increased incidence compared to traditionally common cancers of the oral c...
Source: Journal of Cancer Policy - Category: Cancer & Oncology Source Type: research
A biomarker blood test can accurately determine if patients with oropharyngeal...Read more on AuntMinnie.comRelated Reading: ASTRO: Prostate RT works better than expected in black men ASTRO: SABR is effective for oligometastatic cancers ASTRO: Weekly breast radiation therapy is safe ASTRO: AI's rad therapy future is in predicting outcomes ASTRO: SBRT works well for less risky prostate cancer
Source: Headlines - Category: Radiology Source Type: news
(American Society for Radiation Oncology) A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy. Findings will be presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Erbitux | Health | Hematology | Oropharyngeal Cancer | Radiation Therapy